What was the total amount Viemed spent on share repurchases in the first half of 2026?

Viemed spent $6.8 million on share repurchases in the first half of 2026, according to the company's condensed consolidated statements of cash flows. This included the Q2 repurchase of 530,802 shares at $9.65 per share for $5.1 million.

Is this a new share repurchase program authorization?

No, this filing reports execution under an existing share repurchase program. The filing does not announce a new authorization or provide details on the authorization amount, authorization date, or remaining authorization balance. It reports only the Q2 2026 repurchase activity.

How does the $9.65 buyback price compare to Viemed's recent valuation?

The filing does not disclose the stock price at the time of repurchase or provide comparative valuation metrics. The $9.65 average price represents the company's actual execution cost during Q2 2026 but lacks context for peer or historical comparison without external market data.

What percentage of shares outstanding did Viemed repurchase in Q2?

Viemed repurchased approximately 1.4% of its diluted weighted-average share count in Q2 2026 (530,802 shares of 41.1 million weighted average diluted shares). The company had 38.1 million shares issued and outstanding as of June 30, 2026.

How much free cash flow does Viemed generate, and is the buyback sustainable?

Viemed generated $34.4 million in free cash flow for the trailing twelve months ended June 30, 2026, and $60.8 million in operating cash flow over the same period. At an annual run-rate of ~$20 million in buyback spending (based on Q2 pace), repurchases represent less than 60% of trailing free cash flow, suggesting the program is sustainable without constraining growth investment or financial flexibility.

What is the execution mechanism—open-market purchases, ASR, or another method?

The filing does not specify the execution mechanism for the Q2 2026 repurchases. Standard practice for public companies is Rule 10b-18 open-market purchases unless otherwise disclosed, but this filing contains no such detail. Investors should refer to the company's 10-K or other SEC filings for the buyback program terms and authorization.

VMD 8-K Filed 2026-08-03 Execution disclosure

Viemed repurchased 530,802 shares at $9.65 average in Q2 2026

Company spent $5.1M on buybacks in second quarter as part of ongoing share repurchase program.

Shares repurchased531K

Avg price paid$9.65

MechanismNot specified

What the filing says

Viemed Healthcare, Inc. (NASDAQ: VMD) repurchased and cancelled 530,802 common shares during the second quarter of 2026 at an average price of $9.65 per share, for a total cost of $5.1 million (excluding taxes). The buyback activity was executed under the Company's share repurchase program.

For the first half of 2026, Viemed spent $6.8 million on share repurchases, as reflected in the cash flow statement. The company reported strong operational performance in Q2 2026, with net revenues reaching a record $78.1 million and net income of $2.8 million, or $0.07 per diluted share. Free cash flow for the trailing twelve months ended June 30, 2026 totaled $34.4 million, supporting the company's ability to execute share buybacks while maintaining its balance sheet.

The execution mechanism for the repurchases was not specified in this filing. Management noted in forward-looking statements that share repurchases remain part of the company's capital allocation priorities as it maintains financial flexibility to invest in growth initiatives.

During the second quarter of 2026, the Company repurchased and cancelled 530,802 common shares under its share repurchase program at a cost of $5.1 million (excluding taxes), representing an average buyback price of $9.65 per share. — VIEMED HEALTHCARE, INC. 8-K filing · View on SEC EDGAR →

What this means

Viemed's Q2 2026 share repurchases represent an execution of its ongoing buyback program rather than a new authorization announcement. At an average price of $9.65 per share, the company repurchased roughly 1.4% of its weighted-average diluted share count for the quarter (530,802 shares of 41.1 million weighted average shares). The $5.1 million quarterly spend is modest relative to the company's trailing twelve-month free cash flow of $34.4 million and its operating cash flow, indicating manageable capital deployment that does not materially constrain other strategic priorities or financial flexibility. The buyback reduces share count modestly but signals management confidence in financial position amid record revenue generation.

Frequently asked questions

What was the total amount Viemed spent on share repurchases in the first half of 2026?: Viemed spent $6.8 million on share repurchases in the first half of 2026, according to the company's condensed consolidated statements of cash flows. This included the Q2 repurchase of 530,802 shares at $9.65 per share for $5.1 million.
Is this a new share repurchase program authorization?: No, this filing reports execution under an existing share repurchase program. The filing does not announce a new authorization or provide details on the authorization amount, authorization date, or remaining authorization balance. It reports only the Q2 2026 repurchase activity.
How does the $9.65 buyback price compare to Viemed's recent valuation?: The filing does not disclose the stock price at the time of repurchase or provide comparative valuation metrics. The $9.65 average price represents the company's actual execution cost during Q2 2026 but lacks context for peer or historical comparison without external market data.
What percentage of shares outstanding did Viemed repurchase in Q2?: Viemed repurchased approximately 1.4% of its diluted weighted-average share count in Q2 2026 (530,802 shares of 41.1 million weighted average diluted shares). The company had 38.1 million shares issued and outstanding as of June 30, 2026.
How much free cash flow does Viemed generate, and is the buyback sustainable?: Viemed generated $34.4 million in free cash flow for the trailing twelve months ended June 30, 2026, and $60.8 million in operating cash flow over the same period. At an annual run-rate of ~$20 million in buyback spending (based on Q2 pace), repurchases represent less than 60% of trailing free cash flow, suggesting the program is sustainable without constraining growth investment or financial flexibility.
What is the execution mechanism—open-market purchases, ASR, or another method?: The filing does not specify the execution mechanism for the Q2 2026 repurchases. Standard practice for public companies is Rule 10b-18 open-market purchases unless otherwise disclosed, but this filing contains no such detail. Investors should refer to the company's 10-K or other SEC filings for the buyback program terms and authorization.

execution rule-10b-18 mid-cap healthcare-sector q2-2026

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.